These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37104919)

  • 1. Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233].
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2023 Jun; 563():216196. PubMed ID: 37104919
    [No Abstract]   [Full Text] [Related]  

  • 2. DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer.
    Moskovich D; Alfandari A; Finkelshtein Y; Weisz A; Katzav A; Kidron D; Edelstein E; Veroslavski D; Perets R; Arbib N; Kadan Y; Fishman A; Lerer B; Ellis M; Ashur-Fabian O
    Cancer Lett; 2021 Mar; 501():224-233. PubMed ID: 33221455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment.
    Moskovich D; Finkelshtein Y; Alfandari A; Rosemarin A; Lifschytz T; Weisz A; Mondal S; Ungati H; Katzav A; Kidron D; Mugesh G; Ellis M; Lerer B; Ashur-Fabian O
    Oncogene; 2021 Nov; 40(44):6248-6257. PubMed ID: 34556811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum to "Circadian clock gene NPAS2 promotes reprogramming of glucose metabolism in hepatocellular carcinoma cells" [Canc. Lett. 469 (2020) 498-509].
    Yuan P; Yang T; Mu J; Zhao J; Yang Y; Yan Z; Hou Y; Chen C; Xing J; Zhang H; Li J
    Cancer Lett; 2021 Nov; 521():322-323. PubMed ID: 34521548
    [No Abstract]   [Full Text] [Related]  

  • 5. MicroRNA 214 Is a Potential Regulator of Thyroid Hormone Levels in the Mouse Heart Following Myocardial Infarction, by Targeting the Thyroid-Hormone-Inactivating Enzyme Deiodinase Type III.
    Janssen R; Zuidwijk MJ; Muller A; van Mil A; Dirkx E; Oudejans CB; Paulus WJ; Simonides WS
    Front Endocrinol (Lausanne); 2016; 7():22. PubMed ID: 27014189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corrigendum to "MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer", [Canc. Lett. 399 (2017) 53-63].
    Ou C; Sun Z; Li X; Li X; Ren W; Qin Z; Zhang X; Yuan W; Wang J; Yu W; Zhang S; Peng Q; Yan Q; Xiong W; Li G; Ma J
    Cancer Lett; 2018 Apr; 420():260. PubMed ID: 29429755
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer" [Canc. Lett. 459 (2019 Sep 10) 122-134].
    Liu X; Lu Y; Xu Y; Hou S; Huang J; Wang B; Zhao J; Xia S; Fan S; Yu X; Du Y; Hou L; Li Z; Ding Z; An S; Huang B; Li L; Tang J; Ju J; Guan H; Song B
    Cancer Lett; 2022 Jul; 539():215695. PubMed ID: 35501203
    [No Abstract]   [Full Text] [Related]  

  • 8. Increased type 3 deiodinase expression in papillary thyroid carcinoma.
    Romitti M; Wajner SM; Zennig N; Goemann IM; Bueno AL; Meyer EL; Maia AL
    Thyroid; 2012 Sep; 22(9):897-904. PubMed ID: 22823995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Corrigendum to 'ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2' [Canc. Lett. 427 (2018) 9-17].
    Luo Q; Wu X; Zhang Y; Shu T; Ding F; Chen H; Zhao P; Chang W; Zhu X; Liu Z
    Cancer Lett; 2021 Feb; 498():243. PubMed ID: 33342532
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "SUMOylation of SYNJ2BP-COX16 promotes breast cancer progression through DRP1-mediated mitochondrial fission" [Canc. Lett. 547 (2022) 215871].
    Wang M; Wei R; Li G; Bi HL; Jia Z; Zhang M; Pang M; Li X; Ma L; Tang Y
    Cancer Lett; 2022 Nov; 549():215923. PubMed ID: 36166936
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Rab8A promotes breast cancer progression by increasing surface expression of Tropomyosin-related kinase B" [Canc. Lett. 535 (2022) 215629].
    Liu Y; Zhang Z; Gao X; Ma Q; Yu Z; Huang S
    Cancer Lett; 2022 Jul; 539():215701. PubMed ID: 35527117
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215].
    Zhang B; Ye H; Ren X; Zheng S; Zhou Q; Chen C; Lin Q; Li G; Wei L; Fu Z; Zhang Y; Hu C; Li Z; Chen R
    Cancer Lett; 2022 Nov; 548():215897. PubMed ID: 36050250
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "AGBL2 promotes cancer cell growth through IRGM-regulated autophagy and enhanced Aurora A activity in hepatocellular carcinoma" [Canc. Lett. 414 (2018) 71-80].
    Wang LL; Jin XH; Cai MY; Li HG; Chen JW; Wang FW; Wang CY; Hu WW; Liu F; Xie D
    Cancer Lett; 2022 Jul; 539():215700. PubMed ID: 35525812
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Voltage-gated sodium channel Nav1.5 promotes tumor progression and enhances chemosensitivity to 5-fluorouracil in colorectal cancer" [Canc. Lett. 500 (2021) 119-131].
    Sui Q; Peng J; Han K; Lin J; Zhang R; Ou Q; Qin J; Deng Y; Zhou W; Kong L; Tang J; Xiao B; Li Y; Yu L; Fang Y; Ding PR; Pan Z
    Cancer Lett; 2021 Sep; 516():57-60. PubMed ID: 34091433
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Polypyrimidine tract binding protein 1 promotes lymphatic metastasis and proliferation of bladder cancer via alternative splicing of MEIS2 and PKM." [Canc. Lett. 449 (2019) 31-44].
    Xie R; Chen X; Chen Z; Huang M; Dong W; Gu P; Zhang J; Zhou Q; Dong W; Han J; Wang X; Li H; Huang J; Lin T
    Cancer Lett; 2021 Mar; 500():292-293. PubMed ID: 33390287
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "UBE2T promotes radiation resistance in non-small cell lung cancer via inducing epithelial-mesenchymal transition and the ubiquitination-mediated FOXO1 degradation" [Canc. Lett. 494 (2020) 121-131].
    Yin H; Wang X; Zhang X; Zeng Y; Xu Q; Wang W; Zhou F; Zhou Y
    Cancer Lett; 2022 Sep; 543():215792. PubMed ID: 35718664
    [No Abstract]   [Full Text] [Related]  

  • 17. Decreased expression of the thyroid hormone-inactivating enzyme type 3 deiodinase is associated with lower survival rates in breast cancer.
    Goemann IM; Marczyk VR; Recamonde-Mendoza M; Wajner SM; Graudenz MS; Maia AL
    Sci Rep; 2020 Aug; 10(1):13914. PubMed ID: 32807826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to "MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways" [Canc. Lett. 337 (2013) 226-236].
    Bao L; Yan Y; Xu C; Ji W; Shen S; Xu G; Zeng Y; Sun B; Qian H; Chen L; Wu M; Chen J; Su C
    Cancer Lett; 2020 Mar; 473():198-199. PubMed ID: 31926781
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "Forkhead box D1 promotes EMT and chemoresistance by upregulating lncRNA CYTOR in oral squamous cell carcinoma" [Canc. Lett. 503 (2021) 43-53].
    Chen S; Yang M; Wang C; Ouyang Y; Chen X; Bai J; Hu Y; Song M; Zhang S; Zhang Q
    Cancer Lett; 2022 Jul; 537():215688. PubMed ID: 35459579
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma" [Canc. Lett. 476 (2020) 48-56].
    Leung HW; Lau EYT; Leung CON; Lei MML; Mok EHK; Ma VWS; Cho WCS; Ng IOL; Yun JP; Cai SH; Yu HJ; Ma S; Lee TKW
    Cancer Lett; 2021 Feb; 499():2. PubMed ID: 32563702
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.